Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of colorectal cancer (CRC).
Subjects will be men and women, 40 years of age or older who are scheduled for a colonoscopy. Approximately 7,500 subjects will be enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Average CRC Risk Group | Stool sample collection and blood draw in men and women aged 40 and older with average CRC risk undergoing a standard of care colonoscopy procedure | ||
| Increased CRC Risk Group | Stool sample collection and blood draw in men and women aged 40 and older with increased CRC risk undergoing a standard of care colonoscopy procedure |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Stool-based biomarkers associated with genetic and epigenetic alterations | The outcomes are co-primary. Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in stool from subjects at average risk or increased risk for development of colorectal cancer at the pre-intervention stage. | Stool sample will be collected prior to initiation of bowel preparation for colonoscopy. |
| Blood-based biomarkers associated with genetic and epigenetic alterations. | The outcomes are co-primary. Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects at average risk or increased risk for development of colorectal cancer at the pre-intervention stage. | Point in time blood collection (1 day) at enrollment. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Any previous cancer diagnosis (with the exceptions of basal cell or squamous cell skin cancers) and/or cancer related treatment (e.g. chemotherapy, immunotherapy, radiation, and/or surgery) within the past 5 years.
Subject has a diagnosis or personal history of any of the following conditions, including:
Subject has a family history of:
Subjects with Cronkhite-Canada Syndrome.
IV contrast (e.g. CT and MRI) within 1 day [or 24 hours] of blood collection.
Subject has any condition that in the opinion of the Investigator should preclude participation in the study
Not provided
Not provided
Not provided
Subjects will be men and women, 40 years of age or older who are scheduled for a colonoscopy. Approximately 7,500 subjects will be enrolled.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CCT Research/Fiel Family and Sports Medicine | Tempe | Arizona | 85283 | United States | ||
| GW Research, Inc |
Individual participant data that underlie the results reported in publications of the study will be shared after deidentification. This may include text, tables, figures and appendices. The study protocol and informed consent form will also be shared.
Data will be available from 2 years and ending 4 years after publication. Data will be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.
Proposals for access to data should be directed to clinicaltrials@exactsciences.com. To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement. Researchers are are required to obtain necessary IRB/EC approvals or waivers as applicable to conduct research. Data will available between 2 and 4 years after publication through the Sponsor.
Not provided
Not provided
Not provided
Not provided
Not provided
Residual blood and stool samples may be used for evaluating performance of biomarkers for feasibility and assay development. Sample may be stored for up to 20 years. These blood and stool samples will be de-identified.
| Chula Vista |
| California |
| 91910 |
| United States |
| Marvel Research, LLC | Huntington Beach | California | 92647 | United States |
| Desert Medical Group Inc | Palm Springs | California | 92262 | United States |
| Great Lakes Medical Research, LLC | San Diego | California | 92103 | United States |
| Connecticut Clinical Research Institute, LLC | Hartford | Connecticut | 06016 | United States |
| Yale University | New Haven | Connecticut | 06520 | United States |
| Guardian Angel Research Center | Tampa | Florida | 33614 | United States |
| DM Clinical Research/Southwest Gastroenterology | Oak Lawn | Illinois | 60453 | United States |
| Margaret Mary Health | Batesville | Indiana | 47006 | United States |
| Deaconess Clinic-Mt. Pleasant | Evansville | Indiana | 47725 | United States |
| Deaconess Clinic-Gateway | Newburgh | Indiana | 47630 | United States |
| New Orleans Research Institute | Metairie | Louisiana | 70006 | United States |
| Delta Research Partners | Monroe | Louisiana | 71201 | United States |
| Louisiana Research Center, LLC | Shreveport | Louisiana | 71105 | United States |
| Centennial Medical Group | Elkridge | Maryland | 21075 | United States |
| Capitol Research | Rockville | Maryland | 20850 | United States |
| Great Lakes Medical Research, LLC | East Lansing | Michigan | 48823 | United States |
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
| AGA Clinical Research Associates, LLC | Egg Harbor | New Jersey | 08234 | United States |
| Digestive Disease Care, PC | New Hyde Park | New York | 11040 | United States |
| Digestive Health Partners, PA | Asheville | North Carolina | 28801 | United States |
| Charlotte Gastroenterology and Hepatology, LLC | Charlotte | North Carolina | 28207 | United States |
| Trial Management Associates, LLC | Wilmington | North Carolina | 28403 | United States |
| Great Lakes Medical Research | Beachwood | Ohio | 44122 | United States |
| Family Practice Center of Wooster, Inc./Clinical Trial Developers | Massillon | Ohio | 44647 | United States |
| Great Lakes Gastroenterology Research, LLC | Mentor | Ohio | 44060 | United States |
| Great Lakes Medical Research, LLC | Westlake | Ohio | 44145 | United States |
| Comprehensive Internal Medicine, Inc | Wooster | Ohio | 44691 | United States |
| Great Lakes Medical Research | Erie | Pennsylvania | 16506 | United States |
| Susquehanna Research Group | Harrisburg | Pennsylvania | 17110 | United States |
| Great Lakes Medical Research, LLC | Union City | Tennessee | 38261 | United States |
| MediSync Clinical Research | Austin | Texas | 78726 | United States |
| Northside Gastroenterology | Cypress | Texas | 77429 | United States |
| Vilo Research Group, Inc | Houston | Texas | 77017 | United States |
| Digestive Health Associates | Houston | Texas | 77024 | United States |
| DM Clinical Research/PCP For Life | Magnolia | Texas | 77355 | United States |
| Blue Ridge Medical Research | Lynchburg | Virginia | 24502 | United States |
| Virginia Gastroenterology Institute | Suffolk | Virginia | 23434 | United States |
| Wenatchee Valley Hospital | Wenatchee | Washington | 98801 | United States |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
Not provided
Not provided